This Article Full Text Full Text (PDF) Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Grünwald, H. W. Articles by Jacobson, G. M. Search for Related Content PubMed Articles by Grünwald, H. W. Articles by Jacobson, G. M. Social Bookmarking                            What's this?

When Is Standard Treatment Sufficiently Active to Make Use of a Placebo-Controlled Trial Unethical?

Because this article has no abstract, we have provided an extract of the first 100 words of the full text.

	Investigator Blinding and the Use of Placebos in Randomized Controlled Trials

 
Case Vignette
Mrs K, a 58-year-old white woman living in Manhattan (who spends winters in Florida) was seen by her internist for her yearly check-up. The physician noted eight round, rough, sharply circumscribed skin lesions on the forehead and upper areas of both cheeks, with diameters ranging from 3 to 8 mm. The remainder of Mrs K's examination was normal, and the above-described lesions were limited to her face. The physician referred Mrs K to a dermatologist, who concurred in the diagnosis of actinic keratosis. The dermatologist took scrapings, and the cytology also suggested actinic keratosis.

The dermatologist explained to Mrs K . . . [Click for More]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?